Enterprise Value

5.698B

Cash

2.215B

Avg Qtr Burn

-80.86M

Short % of Float

5.96%

Insider Ownership

0.87%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
QALSODY™ (Tofersen) Details
Amyotrophic lateral sclerosis

Approved

Update

Approved

Quarterly sales

SPINRAZA Details
Spinal muscular atrophy

Approved

Quarterly sales

NDA

Submission

IONIS-APOCIII-LRx (Olezarsen) Details
Familial chylomicronemia syndrome

NDA

Submission

ION363 Details
Amyotrophic lateral sclerosis

Phase 3

Data readout

IONIS-APOCIII-LRx (Olezarsen) Details
Severe hypertriglyceridemia

Phase 3

Data readout

Eplontersen (AKCEA-TTR-LRx) Details
Diabetic cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Transthyretin amyloidosis

Phase 3

Data readout

Phase 3

Update

IONIS-FB-LRx Details
IgA nephropathy

Phase 3

Initiation

Phase 2/3

Data readout

ION839 / AZD2693 Details
Non-alcoholic steatohepatitis

Phase 2b

Data readout

ION224 Details
Non-alcoholic steatohepatitis

Phase 2b

Update

Phase 2

Data readout

IONIS-FB-LRx Details
Geographic atrophy

Phase 2

Data readout

IONIS-AGT-LRx Details
Heart failure, Pulmonary hypertension

Phase 2

Update

Phase 2

Update

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued